<DOC>
	<DOCNO>NCT00575874</DOCNO>
	<brief_summary>The purpose study assess efficacy response rivoglitazone HCl compare pioglitazone HCl placebo-corrected change baseline HbA1c 12 week treatment patient type 2 diabetes .</brief_summary>
	<brief_title>Placebo Active Comparator Controlled Dose Response Study Rivoglitazone Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>type 2 diabetes HbA1c &gt; 6.5 % &lt; 10.0 % FPG &gt; 126 mg/dL ( 7 mmol/L ) &lt; 270 mg/dL ( 15 mmol/L ) History type 1 diabetes History ketoacidosis Current insulin therapy Cpeptide &lt; 0.5ng/mL Imparied hepatic function NYHA Class IIIV cardiac status hospitalization CHF EF &lt; 40 % uncontrolled hypertension</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>rivoglitazone HCl</keyword>
	<keyword>pioglitazone HCl</keyword>
	<keyword>thiazolidinedione</keyword>
	<keyword>peroxisome proliferator-activated receptor gamma ( PPAR gamma )</keyword>
	<keyword>type 2 diabetes mellitus</keyword>
</DOC>